An Open-label, Single Sequence Crossover, Study Investigating the Influence of Secukinumab Treatment on the Pharmacokinetics of Midazolam as a CYP3A4 Substrate in Patients With Moderate to Severe Plaque Psoriasis

Trial Profile

An Open-label, Single Sequence Crossover, Study Investigating the Influence of Secukinumab Treatment on the Pharmacokinetics of Midazolam as a CYP3A4 Substrate in Patients With Moderate to Severe Plaque Psoriasis

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Secukinumab (Primary) ; Midazolam
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Status changed from active, no longer recruiting to completed.
    • 11 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 20 Jan 2016 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top